NCT00790010 - Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2009

Primary Completion Date

June 22, 2018

Study Completion Date

June 22, 2018

Conditions

Melanoma

Interventions

DRUG

Bevacizumab Plus Ipilimumab Cohort 1

Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)

DRUG

Bevacizumab Plus Ipilimumab Cohort 2

Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)

DRUG

Bevacizumab Plus Ipilimumab Cohort 3

Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)

DRUG

Bevacizumab Plus Ipilimumab Cohort 4

Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston